3 December 2018 Oryzon announces First-Patients-in in CLEPSIDRA: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Small Cell Lung Cancer patients
12 November 2018 Oryzon announces First-Patient-in in ALICE: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Acute Myeloid Leukemia patients
2 November 2018 ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2018
26 October 2018 Oryzon Raises EUR 13 Million through a Private Placement with US and European Investors
17 October 2018 ORYZON receives approval to start CLEPSIDRA: a Phase IIa clinical trial in Small Cell Lung Cancer with Iadademstat (ORY-1001)
9 October 2018 Oryzon announces first patient enrolled in REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness
10 September 2018 ORYZON receives approval to start ALICE: a Phase IIa clinical trial in AML with Iadademstat (ORY-1001)
7 September 2018 Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness